Apyx Medical (APYX) Projected to Post Quarterly Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is expected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $10.78 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The company had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $19.12 million. Apyx Medical had a negative return on equity of 114.95% and a negative net margin of 21.22%. On average, analysts expect Apyx Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Apyx Medical Price Performance

Apyx Medical stock opened at $2.89 on Wednesday. The stock’s 50 day moving average is $3.64 and its 200 day moving average is $3.70. Apyx Medical has a one year low of $1.04 and a one year high of $4.50. The firm has a market cap of $120.93 million, a P/E ratio of -10.83 and a beta of 1.35. The company has a debt-to-equity ratio of 2.35, a current ratio of 5.00 and a quick ratio of 4.26.

Wall Street Analyst Weigh In

Several research analysts have issued reports on APYX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a report on Friday, March 27th. Wall Street Zen cut shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. BTIG Research raised shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Wednesday, March 11th. Finally, Craig Hallum boosted their target price on shares of Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Nantahala Capital Management LLC lifted its stake in Apyx Medical by 19.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after acquiring an additional 636,043 shares in the last quarter. Informed Momentum Co LLC bought a new position in shares of Apyx Medical during the fourth quarter valued at about $863,000. 683 Capital Management LLC bought a new position in shares of Apyx Medical during the fourth quarter valued at about $436,000. Marshall Wace LLP purchased a new position in Apyx Medical during the fourth quarter worth about $378,000. Finally, Millennium Management LLC purchased a new position in Apyx Medical during the fourth quarter worth about $324,000. Institutional investors own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.